Search the Newsreel

Ascent Industries (NASDAQ:ACNT) Releases Earnings Results

Is Ascent Industries Co (ACNT) Turned Around After Q2 Earnings W

Indian Metals & Ferro Alloys Q1 FY27: Robust Demand Drives Record Profitability

Ascent Industries Co. (NASDAQ: ACNT) lifts Q2 sales 37.6% and closes $13.5M deal

Ascent Industries Co. reported a significant increase in Q2 2026 net sales, up 37.6% to $25.7 million, primarily driven by higher volumes and pricing in its continuing operations. The company also completed the acquisition of Midwest Graphic Sales, Inc. and Sigma Coating, Inc. for …

Ascent Industries Q2 Earnings: Sales Up 37.6% | ACNT Stock News

Ascent Industries Co. (ACNT) reported strong second-quarter 2026 results, with net sales increasing 37.6% year-over-year to $25.7 million and Adjusted EBITDA improving by $1.8 million. The recent acquisition of Midwest Graphic Sales, Inc. and Sigma Coatings, Inc. contributed $1.9 million in net sales and …

Allogene Therapeutics Q2 Results: Earnings Call Set for Aug 12

Allogene Therapeutics will report its Q2 2026 financial results and provide a business update on August 12, 2026, after market close, followed by a webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. The company, a clinical-stage biotechnology firm, focuses on developing allogeneic …

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

Allogene Therapeutics announced it will report its second quarter 2026 financial results and provide a business update on August 12, 2026, after market close. This will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. The company, …

Allogene sets Aug. 12 update on cancer and autoimmune disease

Allogene Therapeutics (NASDAQ: ALLO) announced it will report its second-quarter 2026 financial results and provide a business update on August 12, 2026, after the market close. The company will host a live audio webcast and conference call at 2:00 p.m. PT / 5:00 p.m. …

BlackRock Capital Allocation Term Trust (NYSE:BCAT) Trading 0.7% Higher - Here's Why

Indian Metals & Ferro Alloys Reports Q1 Cons Net Profit Of 1.92B Rupees Vs 924M

Guggenheim Active Allocation Fund Revenue Breakdown – BOATS:GUG

This article provides an overview of the Guggenheim Active Allocation Fund (GUG), including its financial information and general company details. It highlights that the market for GUG is closed, and there are no current trades. The content also lists various financial statements, statistics, and …

Form 13D/A BlackRock ESG Capital Allocation Term Trust For: 3 August

This article announces the filing of Form 13D/A for BlackRock ESG Capital Allocation Term Trust, dated August 3rd. It is a brief, one-sentence news item reporting on a regulatory filing. The piece is primarily boilerplate content from Investing.com with the actual news being the …

BlackRock Capital Allocation Term Trust's high ...

BlackRock Capital Allocation Term Trust (BCAT) offers a high yield, but its sustainability is questionable as a significant portion of its distributions are return of capital, risking Net Asset Value (NAV) erosion. The fund's strategy of option writing and a concentrated portfolio, while driving …

REalloys approved for US Army lease arrangement

REalloys Inc. has been conditionally approved for a long-term lease with the U.S. Army at the Tooele Army Depot in Utah. This agreement aims to strengthen domestic supply chains for critical metals and minerals essential for national security. The company plans to develop production …

Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

NEW YORK, July 31, 2026--(BUSINESS WIRE)--Today, BlackRock Resources & Commodities Strategy Trust (NYSE: BCX), BlackRock Enhanced Equity Dividend Trust (NYSE: BDJ), BlackRock Energy and Resources Trust (NYSE: BGR), BlackRock Enhanced International Dividend Trust (NYSE: BGY), BlackRock Health Sciences Trust (NYSE: BME), BlackRock Health Sciences …

BlackRock Capital Allocation Term Trust Revenue Breakdown – SWB:BD8

This page from TradingView provides a high-level overview of BlackRock Capital Allocation Term Trust (SWB:BD8) financials. It indicates that the market is closed with no trades. The article focuses on navigation and structural elements of the TradingView platform rather than detailed financial data for …

Allogene Therapeutics Inc (ALLO) Risk Assessment: Volatility, Financial Risk & Investment Risk

Allogene Therapeutics Inc (ALLO) has a current risk assessment score of 3.70, placing it 115th out of 384 companies in the Biotechnology & Medical Research industry. The company's beta value of 0.47 indicates lower volatility compared to the S&P 500. The report details various …

Ferro-Alloy Resources raises £5.7m, grants share options

Ferro-Alloy tumbles as $8m bond deadline approaches

Ferro-Alloy Resources Seeks US Funding for Vanadium Supply Chain

Ferro-Alloy Resources raises £5.7m through share placement By Investing.com

Saba Capital Management sells BlackRock ESG Capital Allocation Term Trust shares worth $4.62 million

Saba Capital Management sold 306,744 common shares of BlackRock ESG Capital Allocation Term Trust (ECAT) on July 28-29, totaling $4.62 million. Following these transactions, their beneficial ownership in ECAT decreased to 16,146,859 shares. This information was generated using AI based on data from the …

VALLOUREC : AVAILABILITY OF THE INTERIM FINANCIAL REPORT AS OF 30 JUNE 2026

VALLOUREC Availability of the Interim Financial Report as of 30 June 2026 Meudon (France), July 30th 2026 – The Vallourec Interim financial report ended 30 June 2026 has been made available to the public and filed with the French securities regulator (Autorité des Marchés …

Vallourec SA (VLOUF) (H1 2026) Earnings Call Highlights: Strong Cash Generation and Record ...

This article first appeared on GuruFocus. Revenue: Group revenues amounted to $886 million in Q2 2026. EBITDA: Group EBITDA was $190 million, with a margin of 21.4%. Net Income: Net income group share was $45 million. Net Cash: Ended the quarter with a net …

Responsive Playbooks and the GUG Inflection

This article analyzes Guggenheim Active Allocation Fund Of Beneficial Interest (NYSE: GUG), highlighting a weak near-term sentiment and a mid-channel oscillation pattern. It presents an exceptional 13.8:1 risk-reward setup targeting a 3.6% gain against 0.3% risk. The analysis also details institutional trading strategies—Position Trading, …

FDA Grants RMAT, Fast Track Status To Cema-cel For High-Risk Large B-cell Lymphoma; Stock Up

(RTTNews) - Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company, announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to cemacabtagene ansegedleucel, or cema-cel, in Large B-Cell Lymphoma, supported by data from the Phase 2 ALPHA 3 …

Allot Ltd (ALLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Allot Ltd (ALLT), focusing on its current stock price momentum, support and resistance levels, and insights from various technical indicators and moving averages. While the stock's price momentum score is 3.92, indicating range-bound trading between $6.87 and …

BlackRock Capital Allocation Term Trust (BCAT) Gains 1.76%: Key Levels and Technical Outlook - Risk Reversal

Alicon Castalloy approves ₹1,255 mn plant for castings

Vallourec Second Quarter 2026 Results

VALLOUREC Meudon (France), July 30th, 2026 Vallourec, a world leader in premium seamless tubular solutions, announces today its results for the second quarter 2026. The Board of Directors of Vallourec SA, meeting on July 29th 2026, approved the Group's second quarter 2026 Consolidated Financial …

Ascent Industries (ACNT.US) will release its earnings report after market close on August 4.

Form 4 BlackRock ESG Capital Allocation Trust For: 28 July By Investing.com

This article announces the filing of a Form 4 for BlackRock ESG Capital Allocation Trust, specifically for July 28th. Form 4 filings typically disclose transactions by company insiders, providing transparency into their buying and selling activities. The brief piece indicates that this information was …

Allogene rises as FDA offers Fast Track, RMAT tags to cell therapy

Shares of Allogene Therapeutics (ALLO [https://seekingalpha.com/symbol/ALLO]) rose on Wednesday after the U.S. Food and Drug Administration awarded the Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for the company’s cell therapy candidate cema-cel. Also known as cemacabtagene ansegedleucel, the allogeneic CAR T product …

Allogene Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy And Fast Track Designations For Cemacabtagene Ansegedleucel As First-Line Consolidation Therapy For Large B-Cell Lymphoma

Allogene Therapeutics has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA for its investigational CAR T product, cemacabtagene ansegedleucel (cema-cel). These designations are for cema-cel as a first-line consolidation therapy for adult patients with high-risk large B-cell lymphoma …

Allogene Therapeutics stock rises on FDA regulatory designations

Allogene Therapeutics Inc. (NASDAQ:ALLO) shares increased after the FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to its experimental therapy cema-cel. These designations are for treating adult patients with large B-cell lymphoma (LBCL) who test positive for minimal residual disease (MRD) …

Allogene Reports No Minimal Residual Disease in 7 of 12 Cema-Cel Patients

Allogene Therapeutics announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to its investigational allogeneic CAR T therapy cemacabtagene ansegedleucel (cema-cel). These designations are based on interim data from the pivotal ALPHA3 trial, where 58.3% of cema-cel-treated …